News

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight ...
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...
Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...
In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...
A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...
Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...
Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment <li /> Combination of oral PL7737 ...